ENTA investors appear pleased with ABBV’s $2.0B guidance for 2021 Mavyret sales (#msg-161451655). As has been discussed on this board ad nauseam, Mavyret will not have positive growth, but it should have a long tail.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”